Raloxifene Hcl
Categoria
Raloxifene Hcl Nombres de marca, Raloxifene Hcl Analogos
Raloxifene Hcl Marca los nombres de mezcla
Raloxifene Hcl Formula quimica
C28H27NO4S
Raloxifene Hcl RX enlace
http://www.rxlist.com/cgi/generic/raloxif.htm
Raloxifene Hcl FDA hoja
Raloxifene Hcl MSDS (hoja de seguridad de materiales)
Raloxifene Hcl Sintesis de referencia
CD Jones et al., J. Med. Cem. 27, 1057 (1984)
Raloxifene Hcl Peso molecular
473.584 g/mol
Raloxifene Hcl Punto de fusion
143-147oC
Raloxifene Hcl H2O Solubilidad
0.25 mg / L
Raloxifene Hcl Estado
Solid
Raloxifene Hcl LogP
5.749
Raloxifene Hcl Formas de dosificacion
Tableta
Raloxifene Hcl Indicacion
Para la prevención de la osteoporosis en mujeres post-menopáusicas
Raloxifene Hcl Farmacologia
El raloxifeno, un modulador selectivo del receptor de estrógeno (SERM) de la clase benzotiofeno, es similar al tamoxifeno, ya que produce efectos similares al estrógeno en el hueso y el metabolismo lipídico, mientras que antagonizar los efectos del estrógeno sobre el tejido mamario. El raloxifeno disminuye la resorción ósea, aumenta la densidad mineral ósea (DMO) y disminuye la incidencia de fracturas. El raloxifeno se utiliza en la prevención de la menopausia la osteoporosis y el cáncer de mama.
Raloxifene Hcl Absorcion
Aproximadamente el 60% de una dosis oral se absorbe, pero glucuronoconjugación presistémico es muy amplia. La biodisponibilidad absoluta de raloxifeno es del 2,0%
Raloxifene Hcl Toxicidad
No hay información disponible
Raloxifene Hcl Informacion de Pacientes
PATIENT INFORMATION
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
Raloxifene Hcl Organismos afectados
Humanos y otros mamíferos
